Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J-J, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469–475

Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized double-blind trial with placebo. J Clin Oncol 12: 1058–1062

Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412–3425

Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84: 3–10

Egrie JC, Dwyer E, Lykos M, Hitz A, Browne JK (1997) Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO). Blood 90: 56a–57a, (abstract)

Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875–2882

Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218–1234

Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Saven A, Hynes H, Boccia R, O'Byrne J, Colowick AB (2001) A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 84: 17–23

Heatherington AC, Schuller J, Mercer AJ (2001) Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 84: 11–16

Henry DH, Abels RI (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 21: 21–28

Kotasek D, Berg R, Poulsen E, Colowick A The ARANESP 980291 Study Group (2000) Randomized, double-blind, placebo controlled phase I/II dose finding study of ARANESP™ administered once every three weeks in solid tumor patients. Blood 96: 294a–295a, (abstract)

Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874

Macdougall IC (2001) An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dialysis Transplant 16: 14–21

Macdougall IC, Gray S, Elston O, Breen C, Jenkins B, Egrie J (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with Epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392–2395

Miller CB, Jones RJ, Piantodosi S, Abeloff MD, Spivak JL (1990) Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med 332: 1689–1692

Smith RE, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, Brosman S, Bukowski R, Murdock M, Rarick M, Saven A, Colowick AB, Fleishman A, Gayko U, Glaspy J (2001) Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 84: 24–30

Vogelzang NJ, Brietbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scher SL, Portenoy RK The Fatigue Coalition (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of tripart assessment survey. The Fatigue Coalition. Semin Hematol 34: 4–12